Articles On Optiscan Imaging (ASX:OIL)

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

ASX rises +0.5% before sliding back to just +0.18% Broad strength overall, however, with eight sectors higher Soft GDP numbers hide robust economic indicators   ASX slows to a flattish finish The ASX 200 took a sharp dip into negative ter...

Optiscan sponsoring clinical study for head and neck cancer surgery in Perth using its InVue and InForm technology The study is being led by prominent head and neck cancer surgeon Dr Chady Sader Data generated will support US FDA regulato...

Optiscan strives for ‘live biopsies’ for head and neck cancers LTR Pharma wins ethics clearance for fresh erectile dysfunction trial Noxopharm’s quest to cure lupus inches a step further Optiscan (ASX:OIL) will launch an imaging study of...

Highlights New study explores advanced real-time  Collaboration aims to expand digital pathology usage Technology seeks to deliver stronger surgical insights The short selling sector continues to shift as innovative medical techno...

Optiscan Imaging (ASX: OIL) has partnered with Australian Clinical Labs to launch the nation’s first-in-human head and neck cancer imaging study utilising the InVue and InForm digital pathology devices.

Optiscan (ASX:OIL) is redefining real-time diagnostics with its breakthrough confocal endomicroscopy technology. This latest epsiode of Who’s Who, host Tylah Tully unpacks the Melbourne-based Optiscan, which is the only company delivering s...

Optiscan signs collaboration deal with Australian Clinical Labs to support rollout and testing of its InForm digital pathology platform Deal enables InForm to be validated in real-world conditions with imaging data collected from broad ran...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Optiscan Imaging led the biotech pack in October, while some of the Big Four stocks were late scratchings Does CSL have an iron deficiency? Weebit Nano ‘mini me’ Dorsavi quietly jockeys for position in the high-stakes chip race   The ASX...

CSL shares are having a stinker of a day after gloomy update  Syntara says the FDA has provided a clear path for its next myelofibrosis trial Optiscan reports an “eventful” September quarter   Investor hopes for the dawn of a recovery at...

October marks Global Breast Cancer Awareness Month with several ASX companies working to advance early detection and treatments for better outcomes Imagion’s first-of-its-kind imaging agent tech MagSense uses targeted nanoparticles to enha...

Somnomed has a leading global share of the oral sleep device market, but its performance has lagged over the years CEOs Karen Borg and Amrita Blickstead have presided over a financial recovery Oral appliance therapy can be a cheaper altern...

ASX 200 closes 0.13% lower on Friday, despite eight of 11 sectors higher  Tech sector leads gains while resource stocks weigh heavily Trigg Minerals continues to progress its proposed US Nasdaq listing    The ASX 200 ended the week lower...

ASX goes on the offence, up 1.13pc 8 of 11 sectors higher, led by healthcare and materials Strength in resources, banks and healthcare drive gains   ASX roars higher, rotating back out of defensive sectors After playing it safe yesterday,...

Optiscan’s confocal laser endomicroscopy promises to revolutionise cancer surgery so that it’s done right first time, every time The company has turned to upending outdated pathology practices with real-time and remote analysis The company...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

ASX up 1pc on broad market gains Strong movement in big banks, lift almost 2pc Profit taking in gold stocks drives All Ords Gold lower Investors devour the dip It was a story of swift recovery on the ASX 200 today as falling bond yields...

ASX plunges in worst performance since April All 11 sectors and every index lower Rising bond yields a core driver of market weakness A sea of red The ASX 200 has had its worst trading day since April’s Liberation Day, plunging a full 16...

ASX sheds 45.5 points or 0.51pc Tech leads losses, chasing Wall Street lower Near record gold prices pump up All Ord Gold index almost 6pc Tech pain undercuts gold gains The tech sector followed its Wall Street counterpart lower, draggin...

Maximising efficiency in healthcare, pharmaceutical development and manufacturing has become a top priority Nanosonics’ flagship Trophon system becomes standard of care for cleaning ultrasound probes in several countries Optiscan transform...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

EchoSolv enters Mayo’s gauntlet for FDA nod Echo’s AI flags heart failure before it hits the fan Other ASX stocks that have trialled with Mayo   On July 1, Echo IQ released an announcement that made cardiologists sit a little straighter....

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

Optiscan initiates first in-human breast cancer study Enrolment for recruitment into the study will begin at the Royal Melbourne Hospital A total of 50 patients undergoing breast-conserving procedures will be recruited   Special Report:...

Tylah Tully chats with Optiscan Imaging (ASX:OIL) CEO Camille Farah about the company’s new agreement with Long Grove Pharmaceuticals, pairing Long Grove’s fluorescein drug, AK-FLUOR, in combination with OIL’s imaging technology in clinical...

ASX 200 Banks index adds 0.49pc Eight of 11 sectors down, with losses led by industrials sliding -1.40pc Uranium and oil stocks lift energy sector out of the negative The ASX retreated in trade today, shedding 0.36% with 8 of 11 sectors s...

Optiscan enters exclusive five-year collaboration deal with US-based drug company Long Grove Pharmaceuticals Companies to work together to develop new intended uses for Long Grove’s intravenous fluorescein sodium contrast agent AK-FLUOR AK...

ASX sets new record close at 8587.2 points, breaking February 2025 heights 10 of 11 sectors on the up, with only Industrials dragging (-0.08pc) All Tech and 200 Banks indices add more than 1pc each It’s been a convincing day of gains on t...

Optiscan reveals novel microscopic imaging device InSpecta, designed for veterinary medicine Device expands Optiscan’s product portfolio and entry into lucrative, high-growth global veterinary market Being tested at University of Minnesota...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Highlights ASX 200 futures signal a stronger open amid renewed global optimism US indices rally as tariff tensions ease and consumer sentiment improves Key ASX companies including ASX:GMG, ASX:WEB, ASX:FPH, ASX:IFT and ASX:M...

Highlights: ASX 200 lifted by strong performances in financials, technology, and copper-related stocks Infocus Group (ASX:IFG) and OpenLearning (ASX:OLL) secure major contracts driving tech sector gains Rising copper momentu...

ASX lifts 0.56pc on tech and financials strength Mine closure, takeover offer perks up copper stocks Lucrative software contracts boost tech sector   The ASX gained momentum throughout the day, lifting from just 0.14% at lunchtime to add...

The ASX200 closed up 0.56% at 8,407 points. IT was the leading sector, up 1.25%, followed by Financials, up 1.1%, and Health Care 0.9%. Real Estate was the biggest loser, down 0.4%, followed by Telecommunication, up 0.3%, and Staples,...

 Optiscan’s telepathology streaming software enables surgeons to have secure real-time access to pathologists – no matter where they are in the world 4D Medical’s device probes the lung’s innards without the nasties Painchek signs a US dis...

ASX just scrapes into the green in last hour of trade, up just 0.13pc Nasdaq gains lay runway for Info Tech strength Tariff pause continues to push up oil and energy stocks After all the excitement of the last few weeks, the ASX appears t...

Compumedics’ MEG unit can scan adult and kid’s heads at the same time – a technically tricky task Microba’s comprehensive gut testing reveals all is not well in the tummy region Trump’s drug pricing blitz should be “immaterial”, says Telix...

Optiscan Imaging (ASX: OIL) and US medical group Mayo Clinic have joined forces to advance the development of a digital confocal laser endomicroscopic imaging system for use in robot-assisted breast cancer surgery. The two parties are condu...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Healthcare and medical manufacturing in Australia is gaining momentum supported by initiatives from federal and state governments CSL, IDT Australia, Optiscan and Trajan Group among healthcare companies with manufacturing facilities in Mel...

What the Facts on the field of pathology? How does it work? Why modern day pathology is still analogue? What  difficulties do pathologist face? Pathology still lives in the analogue world when the rest of us live in a digital world. Optisca...

ASX takes a hit on tariff fears Gold hits new records again RBA rates decision in focus   The ASX copped a big blow on Monday, falling by 1.6% and wiping out more than $30 billion in market value as concerns over the looming US tariffs ra...

Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode Nadine chats to Dr Camile Farah CEO and Managing Director of Optiscan (ASX:OIL) about their recently unveil...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Stockhead’s Fraser Palamara sits down with Managing Director of  Optiscan (ASX:OIL) Dr Camile Farah  to get the short end of the long story, on the company’s latest news. Optiscan has unveiled its first-in-class, next-generation microscopic...

Optiscan has unveiled its first-in-class, next-generation microscopic medical imaging device InForm The device is designed to revolutionise traditional analogue pathology workflows through digitalisation InForm has potential to change the...

EBOS has the prescription for growth, despite the loss of its Chemist Warehouse supply contract Thanks to vapes and medicinal cannabis, chemist supplier PharmX is on a high Optiscan does the Big Reveal on its pathology imaging device   Tr...

Highlights EBOS Group (EBO) faces financial headwinds following a loss of a key supply contract PharmX (PHX) captures evolving pharmacy trends through growing demand for vapes and medicinal cannabis Optiscan (OIL) introduces innovativ...

  Optiscan initiates pre-clinical gastrointestinal study with a major German university To support the study, Optiscan has completed its first prototype to collect images from the gastrointestinal tract The study will assess Optiscan’s Gen...